Fevipiprant 99% White powder cas872365-14-5 senwayer

Contact me for more details

Whatsapp:+8613659820406

Wickr:Amy0033

Fevipiprant is an oral, non-steroidal, highly selective, reversible antagonist of the DP2 receptor that prevents the binding of PGD2 [5] and its metabolites to the DP2 receptor. Binding of fevipiprant to the DP2 receptor reduces the migration and activation of eosinophils, basophils, innate lymphoid cells (ILC-2) and T lymphocytes into the airway tissues and reduces the PGD2-driven release of Th2 cytokines [6, 7]. Post hoc subgroup analysis of a Phase 2 proof of concept study, in patients with reduced lung function at baseline, showed that fevipiprant 500 mg once daily significantly improved pre-dose trough forced expiratory volume in one second (FEV1) and asthma control (assessed with the Asthma Control Questionnaire [ACQ] scores) compared with placebo [8] despite the absence of significant improvements in these measurements across the overall population. Other Phase 2 studies showed that optimal dose response was achieved with fevipiprant 150 mg once daily [9] and that patients treated with fevipiprant 225 mg twice daily had a 3.5-times greater reduction in sputum eosinophils compared with placebo, although a significant effect on blood eosinophil count was not demonstrated